O	0	7	Quality
O	8	10	of
O	11	15	life
O	16	18	of
O	19	33	postmenopausal
O	34	39	women
O	40	42	in
O	43	46	the
O	47	51	ATAC
O	52	53	(
B-intervention	53	54	"
I-intervention	54	62	Arimidex
I-intervention	62	63	"
I-intervention	63	64	,
I-intervention	65	74	tamoxifen
I-intervention	74	75	,
I-intervention	76	81	alone
I-intervention	82	84	or
I-intervention	85	87	in
I-intervention	88	99	combination
O	99	100	)
O	101	106	trial
O	107	112	after
O	113	123	completion
O	124	126	of
O	127	128	5
O	129	134	years
O	134	135	'
O	136	144	adjuvant
O	145	154	treatment
O	155	158	for
O	159	164	early
O	165	171	breast
O	172	178	cancer
O	178	179	.

O	180	183	The
O	184	190	impact
O	191	193	of
O	194	203	treatment
O	204	206	on
O	207	213	health
O	213	214	-
O	214	221	related
O	222	229	quality
O	230	232	of
O	233	237	life
O	238	239	(
O	239	244	HRQoL
O	244	245	)
O	246	248	is
O	249	251	an
O	252	261	important
O	262	275	consideration
O	276	278	in
O	279	282	the
O	283	291	adjuvant
O	292	301	treatment
O	302	304	of
O	305	313	operable
O	314	320	breast
O	321	327	cancer
O	327	328	.

O	329	333	Here
O	334	336	we
O	337	343	report
O	344	350	mature
O	351	356	HRQoL
O	357	365	outcomes
O	366	370	from
O	371	374	the
O	375	379	ATAC
O	380	385	trial
O	385	386	,
O	387	396	comparing
O	397	408	anastrozole
O	409	413	with
B-control	414	423	tamoxifen
O	424	426	as
O	427	434	primary
O	435	443	adjuvant
O	444	451	therapy
O	452	455	for
B-eligibility	456	470	postmenopausal
I-eligibility	471	476	women
I-eligibility	477	481	with
I-eligibility	482	491	localized
I-eligibility	492	498	breast
I-eligibility	499	505	cancer
O	505	506	.

O	507	515	Patients
O	516	525	completed
O	526	529	the
O	530	540	Functional
O	541	551	Assessment
O	552	554	of
O	555	561	Cancer
O	562	569	Therapy
O	569	570	-
O	570	576	Breast
O	577	578	(
O	578	582	FACT
O	582	583	-
O	583	584	B
O	584	585	)
O	586	599	questionnaire
O	600	604	plus
O	605	614	endocrine
O	615	623	subscale
O	624	625	(
O	625	627	ES
O	627	628	)
O	629	631	at
O	632	640	baseline
O	640	641	,
O	642	643	3
O	644	647	and
O	648	649	6
O	650	656	months
O	656	657	,
O	658	661	and
O	662	667	every
O	668	669	6
O	670	676	months
O	677	687	thereafter
O	687	688	.

O	689	697	Baseline
O	698	713	characteristics
O	714	716	in
O	717	720	the
O	721	726	HRQoL
O	727	730	sub
O	730	731	-
O	731	739	protocol
O	740	744	were
O	745	749	well
O	750	758	balanced
O	759	766	between
O	767	770	the
O	771	782	anastrozole
O	783	784	(
O	784	785	n
O	786	787	=
B-intervention-participants	788	791	335
O	791	792	)
O	793	796	and
O	797	806	tamoxifen
O	807	808	(
O	808	809	n
O	810	811	=
B-control-participants	812	815	347
O	815	816	)
O	817	823	groups
O	824	826	in
O	827	830	the
O	831	838	primary
O	839	847	analysis
O	848	858	population
O	858	859	.

O	860	862	As
O	863	867	with
O	868	878	previously
O	879	888	published
O	889	896	results
O	897	899	at
O	900	901	2
O	902	907	years
O	907	908	,
O	909	914	there
O	915	918	was
O	919	921	no
O	922	935	statistically
O	936	947	significant
O	948	958	difference
O	959	961	in
O	962	965	the
B-outcome-Measure	966	971	Trial
I-outcome-Measure	972	979	Outcome
I-outcome-Measure	980	985	Index
I-outcome-Measure	986	988	of
I-outcome-Measure	989	992	the
I-outcome-Measure	993	997	FACT
I-outcome-Measure	997	998	-
I-outcome-Measure	998	999	B
O	999	1000	,
O	1001	1004	the
O	1005	1012	primary
O	1013	1021	endpoint
O	1022	1024	of
O	1025	1028	the
O	1029	1034	study
O	1034	1035	,
O	1036	1043	between
O	1044	1054	treatments
O	1055	1057	at
O	1058	1059	5
O	1060	1065	years
O	1065	1066	.

O	1067	1072	There
O	1073	1077	were
O	1078	1080	no
O	1081	1094	statistically
O	1095	1106	significant
O	1107	1118	differences
O	1119	1126	between
O	1127	1136	treatment
O	1137	1143	groups
O	1144	1146	in
B-outcome	1147	1149	ES
I-outcome	1150	1155	total
I-outcome	1156	1162	scores
O	1162	1163	.

O	1164	1174	Consistent
O	1175	1179	with
O	1180	1183	the
O	1184	1185	2
O	1185	1186	-
O	1186	1190	year
O	1191	1199	analysis
O	1199	1200	,
O	1201	1206	there
O	1207	1211	were
O	1212	1223	differences
O	1224	1231	between
O	1232	1241	treatment
O	1242	1248	groups
O	1249	1251	in
O	1252	1259	patient
O	1259	1260	-
O	1260	1268	reported
O	1269	1273	side
O	1274	1281	effects
O	1281	1282	:
B-outcome	1283	1291	diarrhea
O	1292	1293	(
O	1293	1304	anastrozole
B-iv-bin-percent	1305	1306	3
I-iv-bin-percent	1306	1307	.
I-iv-bin-percent	1307	1308	1
I-iv-bin-percent	1308	1309	%
O	1310	1312	vs
O	1312	1313	.
O	1314	1323	tamoxifen
B-cv-bin-percent	1324	1325	1
I-cv-bin-percent	1325	1326	.
I-cv-bin-percent	1326	1327	3
I-cv-bin-percent	1327	1328	%
O	1328	1329	)
O	1329	1330	,
B-outcome	1331	1338	vaginal
I-outcome	1339	1346	dryness
O	1347	1348	(
B-iv-bin-percent	1348	1350	18
I-iv-bin-percent	1350	1351	.
I-iv-bin-percent	1351	1352	5
I-iv-bin-percent	1352	1353	%
O	1354	1356	vs
O	1356	1357	.
B-cv-bin-percent	1358	1359	9
I-cv-bin-percent	1359	1360	.
I-cv-bin-percent	1360	1361	1
I-cv-bin-percent	1361	1362	%
O	1362	1363	)
O	1363	1364	,
B-outcome	1365	1375	diminished
I-outcome	1376	1382	libido
O	1383	1384	(
B-iv-bin-percent	1384	1386	34
I-iv-bin-percent	1386	1387	.
I-iv-bin-percent	1387	1388	0
I-iv-bin-percent	1388	1389	%
O	1390	1392	vs
O	1392	1393	.
B-cv-bin-percent	1394	1396	26
I-cv-bin-percent	1396	1397	.
I-cv-bin-percent	1397	1398	1
I-cv-bin-percent	1398	1399	%
O	1399	1400	)
O	1400	1401	,
O	1402	1405	and
B-outcome	1406	1417	dyspareunia
O	1418	1419	(
B-iv-bin-percent	1419	1421	17
I-iv-bin-percent	1421	1422	.
I-iv-bin-percent	1422	1423	3
I-iv-bin-percent	1423	1424	%
O	1425	1427	vs
O	1427	1428	.
B-cv-bin-percent	1429	1430	8
I-cv-bin-percent	1430	1431	.
I-cv-bin-percent	1431	1432	1
I-cv-bin-percent	1432	1433	%
O	1433	1434	)
O	1435	1439	were
O	1440	1453	significantly
O	1454	1458	more
O	1459	1467	frequent
O	1468	1472	with
O	1473	1484	anastrozole
O	1485	1493	compared
O	1494	1496	to
O	1497	1506	tamoxifen
O	1506	1507	.

B-outcome	1508	1517	Dizziness
O	1518	1519	(
B-iv-bin-percent	1519	1520	3
I-iv-bin-percent	1520	1521	.
I-iv-bin-percent	1521	1522	1
I-iv-bin-percent	1522	1523	%
O	1524	1526	vs
O	1526	1527	.
B-cv-bin-percent	1528	1529	5
I-cv-bin-percent	1529	1530	.
I-cv-bin-percent	1530	1531	4
I-cv-bin-percent	1531	1532	%
O	1532	1533	)
O	1534	1537	and
B-outcome	1538	1545	vaginal
I-outcome	1546	1555	discharge
O	1556	1557	(
B-iv-bin-percent	1557	1558	1
I-iv-bin-percent	1558	1559	.
I-iv-bin-percent	1559	1560	2
I-iv-bin-percent	1560	1561	%
O	1562	1564	vs
O	1564	1565	.
B-cv-bin-percent	1566	1567	5
I-cv-bin-percent	1567	1568	.
I-cv-bin-percent	1568	1569	2
I-cv-bin-percent	1569	1570	%
O	1570	1571	)
O	1572	1576	were
O	1577	1590	significantly
O	1591	1595	less
O	1596	1604	frequent
O	1605	1609	with
O	1610	1621	anastrozole
O	1622	1630	compared
O	1631	1633	to
O	1634	1643	tamoxifen
O	1643	1644	.

O	1645	1647	In
O	1648	1652	this
O	1652	1653	,
O	1654	1657	the
O	1658	1663	first
O	1664	1670	report
O	1671	1673	of
O	1674	1679	HRQoL
O	1680	1684	over
O	1685	1686	5
O	1687	1692	years
O	1693	1695	of
O	1696	1703	initial
O	1704	1712	adjuvant
O	1713	1720	therapy
O	1721	1725	with
O	1726	1728	an
O	1729	1738	aromatase
O	1739	1748	inhibitor
O	1748	1749	,
O	1750	1752	we
O	1753	1761	conclude
O	1762	1766	that
O	1767	1778	anastrozole
O	1779	1782	and
O	1783	1792	tamoxifen
O	1793	1796	had
O	1797	1804	similar
O	1805	1812	impacts
O	1813	1815	on
O	1816	1821	HRQoL
O	1821	1822	,
O	1823	1828	which
O	1829	1832	was
O	1833	1843	maintained
O	1844	1846	or
O	1847	1855	slightly
O	1856	1864	improved
O	1865	1871	during
O	1872	1875	the
O	1876	1885	treatment
O	1886	1892	period
O	1893	1896	for
O	1897	1901	both
O	1902	1908	groups
O	1908	1909	.
